Bumin hospital
Seoul, South Korea
NCT Number: NCT07342062
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fed state.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration (DA-1229_01 one tablet once a day)
single dose administration (DA-1229_01-R one tablet once a day)
Time frame: pre-dose~24 hours post-dose
Area Under the Curve
Time frame: pre-dose~24 hours post-dose
Maximum Plasma Concentration
Dong-A ST Co., Ltd.
Industry
An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fed State
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details